SR 57227A

Drug Profile

SR 57227A

Alternative Names: SR 57227

Latest Information Update: 22 Aug 1997

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antidepressants
  • Mechanism of Action Serotonin 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 22 Aug 1997 A study has been added to the pharmacokinetics section
  • 15 Dec 1996 Discontinued-II for Depression in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top